Systematic review with meta-analysis: Long-term outcomes of faecal microbiota transplantation for Clostridium difficile infection

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue 4, 2016, Pages 445-457

  Li, Y T ^a,b,c   Cai, H F ^a,b,c   Wang, Z H ^a,b,c   Xu, J ^a,b,c   Fang, J Y ^a,b,c  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c School of Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; AUTOIMMUNE DISEASE; CLINICAL EFFECTIVENESS; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE EXACERBATION; FACTORIAL ANALYSIS; FECES MICROFLORA; FECES MICROFLORA TRANSPLANTATION; FOLLOW UP; HUMAN; INFLAMMATORY BOWEL DISEASE; META ANALYSIS; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; THERAPY EFFECT; UPPER GASTROINTESTINAL TRACT; ADVERSE EFFECTS; AGE; CLOSTRIDIUM INFECTIONS; FECAL MICROBIOTA TRANSPLANTATION; FECES; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES; RECURRENT DISEASE;

AGE FACTORS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FECAL MICROBIOTA TRANSPLANTATION; FECES; HUMANS; OBSERVATIONAL STUDIES AS TOPIC; RECURRENCE; RISK FACTORS;

EID: 84954398066     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13492     Document Type: Review

References (59)

1. Ananthakrishnan AN,. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol 2011; 8: 17-26.
2. Stranges PM, Hutton DW, Collins CD,. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health 2013; 16: 297-304.
3. Surawicz CM, Brandt LJ, Binion DG, et al,. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108: 478-98.
4. Debast SB, Bauer MP, Kuijper EJ, et al,. European society of clinical microbiology and infectious diseases: Update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20: 1-26.
5. Cornely OA, Crook DW, Esposito R, et al,. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12: 281-9.
6. Louie TJ, Miller MA, Mullane KM, et al,. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-31.
7. Eiseman B, Silen W, Bascom GS, Kauvar AJ,. Fecal enema as an adjunct in the treatment of pseudomembranous. Surgery 1958; 44: 854-9.
8. Walia R, Garg S, Song Y, et al,. Efficacy of fecal microbiota transplantation in two children with recurrent Clostridium difficile infection and its impact on their growth and gut microbiome. J Pediatr Gastroenterol Nutr 2014; 59: 565-70.
9. Youssef MA, Gavin M,. Fecal microbiota transplant: a case report in an immunosuppressed patient with Crohn's disease and recurrent clostridium difficile infection. Gastroenterology 2013; 144: S626.
10. Vermeire S, Joossens M, Verbeke K, et al,. Pilot study on the safety and efficacy of faecal microbiota transplantation in refractory Crohn's disease. Gastroenterology 2012; 142: S360.
11. Mattila E, Uusitalo-Seppala R, Wuorela M, et al,. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology 2012; 142: 490-6.
12. Gough E, Shaikh H, Manges AR,. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent clostridium difficile infection. Clin Infect Dis 2011; 53: 994-1002.
13. Drekonja D, Reich J, Gezahegn S, et al,. Fecal microbiota transplantation for clostridium difficile infection: a systematic review. Ann Intern Med 2015; 162: 630-8.
14. Rossen NG, MacDonald JK, de Vries EM, et al,. Fecal microbiota transplantation as novel therapy in gastroenterology: a systematic review. W J Gastroenterol 2015; 21: 5359-71.
15. Cammarota G, Ianiro G, Gasbarrini A,. Fecal microbiota transplantation for the treatment of clostridium difficile infection: a systematic review. J Clin Gastroenterol 2014; 48: 693-702.
16. Van Nood E, Vrieze A, Nieuwdorp M, et al,. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407-15.
17. Cammarota G, Masucci L, Ianiro G, et al,. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2015; 41: 835-43.
18. Kassam Z, Lee CH, Yuan Y, Hunt RH,. Fecal microbiota transplantation for clostridium difficile infection: Systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 500-8.
19. Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009; 6: e1000097.
20. National Institute for Clinical Excellence (NICE). Appendix 4. Quality assessment for Case series 2008. 2015-9-9. Available at: http://www.nice.org.uk/guidance/index.jsp?action=download&o=29075 (Accessed date 09 July 2015).
21. Brandt LJ, Aroniadis OC, Mellow M, et al,. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent clostridium difficile infection. Am J Gastroenterol 2012; 107: 1079-87.
22. Bauer MP, Kuijper EJ, van Dissel JT,. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15: 1067-79.
23. Collaboration C. Cochrane handbook for systematic reviews of interventions version 5.1. 0. 2011. Available at: http://handbook.cochrane.org/ (accessed 2014-03-12) [WebCite Cache] 2013.
24. Egger M, Davey Smith G, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
25. Satokari R, Mattila E, Kainulainen V, Arkkila PET,. Simple faecal preparation and efficacy of frozen inoculum in faecal microbiota transplantation for recurrent Clostridium difficile infection-an observational cohort study. Aliment Pharmacol Ther 2015; 41: 46-53.
26. Emanuelsson F, Claesson BEB, Ljungstrom L, Tvede M, Ung KA,. Faecal microbiota transplantation and bacteriotherapy for recurrent Clostridium difficile infection: a retrospective evaluation of 31 patients. Scand J Infect Dis 2014; 46: 89-97.
27. Kelly CR, Ihunnah C, Fischer M, et al,. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 2014; 109: 1065-71.
28. Ray A, Smith R, Breaux J,. Fecal microbiota transplantation for Clostridium difficile infection: the ochsner experience. Ochsner J 2014; 14: 538-44.
29. Dutta SK, Girotra M, Garg S, et al,. Efficacy of combined jejunal and colonic fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 2014; 12: 1572-6.
30. Pathak R, Enuh HA, Patel A, Wickremesinghe P,. Treatment of relapsing clostridium difficile infection using fecal microbiota transplantation. Clin. Exp. Gastroenterol. 2014; 7: 1-6.
31. Kelly CR, De Leon L, Jasutkar N,. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results. J Clin Gastroenterol 2012; 46: 145-9.
32. Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL,. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 2014; 312: 1772-8.
33. Russell GH, Kaplan JL, Youngster I, et al,. Fecal transplant for recurrent Clostridium difficile infection in children with and without inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2014; 58: 588-92.
34. Kassam Z, Hundal R, Marshall JK, Lee CH,. Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection. Arch Intern Med 2012; 172: 191-3.
35. Zainah H, Hassan M, Shiekh-Sroujieh L, Hassan S, Alangaden G, Ramesh M,. Intestinal microbiota transplantation, a simple and effective treatment for severe and refractory Clostridium difficile infection. Dig Dis Sci 2014; 60: 181-5.
36. Aas J, Gessert CE, Bakken JS,. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003; 36: 580-5.
37. Lee CH, Belanger JE, Kassam Z, et al,. The outcome and long-term follow-up of 94 patients with recurrent and refractory Clostridium difficile infection using single to multiple fecal microbiota transplantation via retention enema. Eur J Clin Microbiol Infect Dis 2014; 33: 1425-8.
38. MacConnachie AA, Fox R, Kennedy DR, Seaton RA,. Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series. QJM 2009; 102: 781-4.
39. Hirsch BE, Saraiya N, Poeth K, Schwartz RM, Epstein ME, Honig G,. Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection. BMC Infect Dis 2015; 15: 191.
40. Aroniadis OC, Brandt LJ, Greenberg A, et al,. Long-term follow-up study of fecal microbiota transplantation for severe and/or complicated Clostridium difficile infection: a multicenter experience. J Clin Gastroenterol 2015; doi: 10.1097/MCG.0000000000000374 [Epub ahead of print].
41. Khan MA, Sofi AA, Ahmad U, et al,. Efficacy and safety of, and patient satisfaction with, colonoscopic-administered fecal microbiota transplantation in relapsing and refractory community- and hospital-acquired Clostridium difficile infection. Can J Gastroenterol Hepatol 2014; 28: 434-8.
42. Ghantoji SS, Sail K, Lairson DR, DuPont HL, Garey KW,. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect 2010; 74: 309-18.
43. Kyne L, Warny M, Qamar A, Kelly CP,. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357: 189-93.
44. Leav BA, Blair B, Leney M, et al,. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010; 28: 965-9.
45. Anderson JL, Edney RJ, Whelan K,. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 2012; 36: 503-16.
46. Burke KE, Lamont JT,. Fecal transplantation for recurrent Clostridium difficile infection in older adults: a review. J Am Geriatr Soc 2013; 61: 1394-8.
47. Hu MY, Katchar K, Kyne L, et al,. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 2009; 136: 1206-14.
48. Simor AE,. Diagnosis, management, and prevention of Clostridium difficile infection in long-term care facilities: a review. J Am Geriatr Soc 2010; 58: 1556-64.
49. Johnson S, Clabots CR, Linn FV, Olson MM, Peterson LR, Gerding DN,. Nosocomial Clostridium difficile colonisation and disease. Lancet 1990; 336: 97-100.
50. Persky SE, Brandt LJ,. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am J Gastroenterol 2000; 95: 3283-5.
51. Youngster I, Sauk J, Pindar C, et al,. Fecal microbiota transplant for relapsing clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis 2014; 58: 1515-22.
52. Atkins KA, Kao D,. Potential cost savings associated with timely fecal microbiota transplantation (FMT) for recurrent clostridium difficile infection (RCDI). Gastroenterology 2014; 146: S-252.
53. Bakken JS, Borody T, Brandt LJ, et al,. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011; 9: 1044-9.
54. Mullane KM, Miller MA, Weiss K, et al,. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011; 53: 440-7.
55. Meyer AM, Ramzan NN, Loftus EV Jr, Heigh RI, Leighton JA,. The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol 2004; 38: 772-5.
56. Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ,. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis 2012; 55 (Suppl. 2): S121-6.
57. De Leon LM, Watson JB, Kelly CR,. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 2013; 11: 1036-8.
58. Zainah H, Silverman A,. Fecal bacteriotherapy: a case report in an immunosuppressed patient with ulcerative colitis and recurrent Clostridium difficile infection. Case Rep Infect Dis 2012; 2012: 810943.
59. Duplessis CA, You D, Johnson M, Speziale A,. Efficacious outcome employing fecal bacteriotherapy in severe Crohn's colitis complicated by refractory Clostridium difficile infection. Infection 2012; 40: 469-72.